|
1
|
Shi W, Xu X, Huang R, Yu Q, Zhang P, Xie S, Zheng H, Lu R. Plasma C-MYC level manifesting as an indicator in progression of breast cancer. Biomark Med 2019; 13:917-929. [PMID: 31144531 DOI: 10.2217/bmm-2019-0073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Aim: To investigate whether plasma C-MYC level could be an indicator in clinical progression of breast cancer. Materials & methods: Plasma level of C-MYC expression was detected by quantitative real time PCR and the level of c-myc protein in breast cancer tissues was detected by immunohistochemistry. The expression level of C-MYC mRNA in supernatant of cancer cells culture was measured compared with the nonbreast cancer cells. Results: Plasma C-MYC level was significantly higher in patients with breast cancer than that in the controls, which associated with clinical stages, lymph node status, etc. Receiver operating characteristic curve analysis showed the sensitivity and specificity of plasma C-MYC level for diagnosis of breast cancer were 63.6 and 81.8%, respectively. The expression of c-myc protein in breast cancer tissues was associated with plasma C-MYC level, even C-MYC level in supernatant of cancer cells was elevated. Conclusion: Plasma C-MYC level might be a potential indicator in progression of breast cancer.
Collapse
Affiliation(s)
- Weizhong Shi
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Clinical Laboratory, Shanghai Proton & Heavy Ion Center, Shanghai, PR China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
| | - Xiaofeng Xu
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Clinical Laboratory, Shanghai Proton & Heavy Ion Center, Shanghai, PR China
| | - Ren Huang
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Clinical Laboratory, Shanghai Proton & Heavy Ion Center, Shanghai, PR China
| | - Qi Yu
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Clinical Laboratory, Shanghai Proton & Heavy Ion Center, Shanghai, PR China
| | - Peiru Zhang
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Clinical Laboratory, Shanghai Proton & Heavy Ion Center, Shanghai, PR China
| | - Suhong Xie
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
| | - Hui Zheng
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
| | - Renquan Lu
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, PR China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China
| |
Collapse
|